RXI Pharma (RXII) Posts Mixed Q3 Results

RXI Pharma (NASDAQ: RXII) reported Q3 EPS of ($0.17), $0.05 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $16 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on RXI Pharma (RXII) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Cuprina to buy seven-clinic Singapore healthcare group for S$4M
• Rivian reports Q3 2026 production of 19,751 vehicles